Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing

Background: Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of rivaroxaban and edoxaban dosing by monitoring plasma concentrations (PCs). Methods and Results: We monitored drug PCs in 39...

Descripción completa

Detalles Bibliográficos
Autores principales: Suwa, Michihiro, Nohara, Yuki, Morii, Isao, Kino, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2023
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992501/
https://www.ncbi.nlm.nih.gov/pubmed/36909139
http://dx.doi.org/10.1253/circrep.CR-22-0076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992501/
https://www.ncbi.nlm.nih.gov/pubmed/36909139
http://dx.doi.org/10.1253/circrep.CR-22-0076

Ejemplares similares